Merrifield Resin Assembly With Boc-L-Phenylalanine and Side-Chain Protection

In Boc/Bzl solid-phase peptide synthesis, N-(tert-butoxycarbonyl)-L-phenylalanine (BOC-L-phenylalanine, CAS 13734-34-4) functions as an Nα-protected monomer during chain elongation on 4-methylbenzhydrylamine (MBHA) or phenylacetamidomethyl (PAM) resins. Resin substitution is typically controlled at 0.4–0.8 mmol/g for 1% divinylbenzene-crosslinked polystyrene; lower loadings below 0.3 mmol/g reduce interchain aggregation during aggregation-prone sequences containing L-phenylalanine. Before coupling, the resin is swollen in dichloromethane for 30 min at 20–25°C, then the N-terminal Boc group is removed with 25–50 vol% trifluoroacetic acid in dichloromethane, followed by neutralization with 5 vol% N,N-diisopropylethylamine. BOC-L-phenylalanine is dissolved in anhydrous N,N-dimethylformamide at 0.1–0.5 mol/L and pre-activated with HBTU or DIC/HOBt at a molar ratio of 3.0–5.0 equivalents relative to resin-bound free amine. Coupling proceeds for 30–120 min at 20–25°C; if the Kaiser ninhydrin test remains positive, a double coupling with 2.0–3.0 equivalents is executed. The tert-butoxycarbonyl group is orthogonal to acid-labile side-chain protecting groups such as benzyl, 2-bromobenzyloxycarbonyl, and cyclohexyl, allowing selective removal without premature loss of side-chain protection. Residual N,N-dimethylformamide and dichloromethane must meet ICH Q3C limits when the peptide is advanced to active pharmaceutical ingredient stages: 880 ppm for DMF, 600 ppm for dichloromethane, 720 ppm for tetrahydrofuran. Elemental impurities are assessed under ICH Q3D, and peptide purity is verified by reversed-phase HPLC using USP 621 chromatographic conditions and mass spectrometry. Failure modes observed on production-scale synthesizers include incomplete swelling if dichloromethane is replaced by ethyl acetate, and batch-to-batch variance in BOC-L-phenylalanine particle size when charging from drums with residual moisture above 0.1 wt%; both conditions produce lower first-pass coupling yields. After chain assembly, the peptide is cleaved with hydrogen fluoride/anisole 9:1 at 0°C for 45–90 min or with trifluoromethanesulfonic acid/trifluoroacetic acid for acid-sensitive sequences, then purified by preparative reversed-phase HPLC and lyophilized. Terminal products originating from this route are phenylalanine-containing peptide active pharmaceutical ingredients and regulatory starting materials, including fragments of cyclic peptide APIs such as octreotide-class molecules where an internal L-phenylalanine residue is installed by BOC-L-phenylalanine.

How Does N-Boc-L-Phenylalanine Behave in Solution-Phase Mixed-Anhydride Couplings?

A parallel route for preparing solution-phase peptide fragments uses BOC-L-phenylalanine as the N-terminal or middle amino acid component in mixed-anhydride activations. In a typical coupling, BOC-L-phenylalanine is charged into anhydrous tetrahydrofuran at 0.5–1.0 mol/L and treated with N-methylmorpholine at 1.2–1.5 equivalents; isobutyl chloroformate is added at 1.05–1.1 equivalents while maintaining the jacket temperature at −15°C to −5°C. The resulting mixed anhydride is added to a solution of the amino ester hydrochloride or peptide ester in DMF or dichloromethane; the molar ratio of BOC-L-phenylalanine to nucleophilic amine is maintained at 1.05–1.2 equivalents to drive complete consumption of the higher-value peptide fragment while limiting residual activated acid. Reaction temperature is allowed to rise to 0–20°C over 1–4 h, after which the mixture is diluted with ethyl acetate and washed sequentially with 5 wt% sodium bicarbonate, 1 N hydrochloric acid, and brine. Racemization at the α-carbon of BOC-L-phenylalanine is suppressed by the Boc protecting group and by maintaining temperature below 20°C; the resulting diastereoisomer content is controlled by chiral HPLC with acceptance limits typically not exceeding 0.5–1.0%. Residual solvent limits for this operation are governed by ICH Q3C and USP 467: tetrahydrofuran 720 ppm, ethyl acetate 5000 ppm, and N,N-dimethylformamide 880 ppm. The isolated N-protected phenylalanine dipeptide or tripeptide fragments are used as regulatory starting materials for subsequent fragment condensation; terminal products include protected peptide intermediates for generic pharmaceutical peptides, particularly sequence segments containing L-phenylalanine at non-terminal positions where the Boc group remains until final acidolysis with 30–50 vol% TFA. Published process data for this specific mixed-anhydride configuration is limited for high-volume campaign scales, but laboratory batches consistently show that anhydrous conditions and rapid addition of isobutyl chloroformate minimize symmetric anhydride formation.

When Carboxy-Terminal L-Phenylalanine Residues Require Fragment Condensation

During preparation of longer peptide chains, BOC-L-phenylalanine is sometimes employed as the N-terminal component of a protected peptide acid in convergent fragment condensation. A protected peptide acid containing an N-terminal BOC-L-phenylalanine is combined with a carboxy-protected peptide fragment in anhydrous DMF or N-methyl-2-pyrrolidone. The acid component is charged at 1.0–1.1 equivalents relative to the amino component; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or N,N′-diisopropylcarbodiimide is used at 1.1–1.5 equivalents together with 1-hydroxybenzotriazole or ethyl 2-cyano-2-(hydroxyimino)acetate at 1.2–1.5 equivalents; N,N-diisopropylethylamine is added at 2.0–3.0 equivalents to maintain pH 8.0–8.5. The reaction is held at 0–4°C for 16–24 h to suppress oxazolone-mediated epimerization at the phenylalanine α-carbon. Process-scale reactors require effective overhead agitation; when linear velocity falls below 0.1 m/s in DMF, mass transfer becomes limiting and the reaction does not reach full conversion within 24 h. The crude condensation product is washed against 5% citric acid and 5% sodium bicarbonate, then dried over anhydrous sodium sulfate and either crystallized from isopropanol/water or purified by preparative reversed-phase HPLC. Residual solvents are again controlled under ICH Q3C; NMP, if used, has a Class 2 limit of 530 ppm and is rarely acceptable without solvent exchange to ethyl acetate because of its high boiling point and occupational exposure issues. The method yields protected peptide fragments that terminate in a C-terminal ester or amide and are further elaborated to phenylalanine-containing peptide APIs, C-terminal phenylalanine amide derivatives, and cyclic peptide precursors. Terminal product classes include peptide hormones, anticancer peptide conjugates under investigational use, and generic peptide intermediates where fragment condensation is the only route that avoids diketopiperazine formation during sequential C-terminal ester activation.

Chiral Amino Alcohol Preparation From N-Boc-L-Phenylalanine

BOC-L-phenylalanine is also a chiral-pool starting material for N-Boc-L-phenylalaninol, an intermediate for oxazaborolidine catalysts used in enantioselective ketone reduction. In this downstream route the Boc-protected amino acid is dissolved in tetrahydrofuran at 0.5–1.0 mol/L and reduced with lithium aluminum hydride at 1.5–2.0 equivalents or with sodium borohydride/iodine under published protocols; the reaction is conducted under nitrogen at 0–25°C for 4–12 h, followed by quenching with ethyl acetate and 10 wt% aqueous Rochelle salt. After phase separation, the organic layer is washed with brine and concentrated to an oil that crystallizes as N-Boc-L-phenylalaninol. The product is then cyclized with borane-dimethylsulfide to generate the oxazaborolidine catalyst. In the final asymmetric reduction of prochiral ketones, the catalyst is charged at 1–10 mol% relative to the ketone substrate, while borane-dimethylsulfide is added at 0.6–1.2 equivalents to the ketone. Reaction temperatures between −20°C and 40°C determine enantiomeric excess; published data indicate that typical production batches achieve 90–99% ee when the catalyst is fresh and the substrate contains less than 0.05 wt% water. Industry compliance for this non-pharmaceutical route generally references ISO 9001:2015 quality management and REACH registration EC 1907/2006 for substance volume tracking; if the resulting chiral alcohol is later incorporated into an API, ICH Q3C and ICH Q7 controls are appended. Terminal product types are homochiral secondary alcohol intermediates for β-blockers, antihistamines, and other single-enantiomer drugs, as well as the oxazaborolidine catalysts themselves, which are sold as fine-chemical reagents.

Automated Peptide Synthesizers Configured for Boc Chemistry Expose Weighing and Solubility Constraints

Automated peptide synthesizers configured for Boc chemistry expose weighing and solubility constraints that are specific to BOC-L-phenylalanine because of its crystalline morphology and limited solubility in low-polarity solvents. On 0.1 mmol and 0.25 mmol scales, the monomer is dispensed as a 0.3 M solution in anhydrous DMF or NMP; the dissolved concentration must remain above 0.25 M to avoid precipitation inside Teflon tubing when room temperature drops below 18°C. The coupling addition ratio is set at 3–5 equivalents of BOC-L-phenylalanine relative to resin-bound amino groups; HBTU is delivered as a 0.45 M solution and DIEA as a 2.0 M solution in DMF. Each cycle uses deprotection with 30 vol% TFA in dichloromethane for 2×10 min, DMF wash steps, and coupling for 45–60 min at 25±2°C. The equipment records UV absorbance at 301 nm during deprotection to quantify the released Boc carbocation, providing real-time coupling efficiency data. Production-scale high-throughput peptide libraries use this parameter to flag cycles with coupling efficiency below 99.0%; if the BOC-L-phenylalanine coupling drops below that threshold, the sequence is automatically double-coupled. Regulatory oversight for research and preclinical peptide batches relies on FDA 21 CFR Part 11 for electronic records and signatures, ISO 9001:2015 for non-clinical quality, and, when transitioned to GMP, ICH Q7. The downstream process terminates with preparative HPLC and lyophilization. Terminal product types are phenylalanine-containing peptide libraries for receptor screening, alanine-scanning analogs, antimicrobial peptide candidates, and custom research peptides for academic and industrial laboratories.